• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Mov Disord . Clinical Profiles and Mortality of COVID-19 Inpatients with Parkinson's Disease in Germany

tetano

Editor, Senior Moderator
Mov Disord


. 2021 May 4.
doi: 10.1002/mds.28586. Online ahead of print.
Clinical Profiles and Mortality of COVID-19 Inpatients with Parkinson's Disease in Germany


Raphael Scherbaum[SUP] 1 [/SUP], Eun Hae Kwon[SUP] 1 [/SUP], Daniel Richter[SUP] 1 [/SUP], Dirk Bartig[SUP] 2 [/SUP], Ralf Gold[SUP] 1 3 [/SUP], Christos Krogias[SUP] 1 [/SUP], Lars T?nges[SUP] 1 3 [/SUP]



Affiliations

Abstract

Background: Comprehensive, nationwide data regarding Parkinson's disease (PD) hospitalizations, coronavirus disease 2019 (COVID-19) in-hospital frequency, and COVID-19-associated inpatient mortality during the first wave of the COVID-19 pandemic are not available.
Objective: To provide a nationwide analysis on hospitalized PD patients in Germany and evaluate the impact of the COVID-19 pandemic.
Methods: We conducted a cross-sectional study using an administrative claims database covering 1468 hospitals and 5,210,432 patient hospitalizations including a total of 30,872 COVID-19[SUP]+[/SUP] cases between January 16 and May 15, 2020.
Results: Compared to 2019, hospitalizations for PD transiently decreased by up to 72.7% in 2020. COVID-19 frequency was significantly higher in the population of 64,434 PD patients (693 being COVID-19[SUP]+[/SUP] ) than in non-PD patients (1.1% vs. 0.6%, P < 0.001), especially in subjects with advanced age (? 65 years). Regarding established COVID-19 risk comorbidities, COVID-19[SUP]+[/SUP] inpatients with PD showed higher incidences than non-PD COVID-19[SUP]+[/SUP] subjects, particularly hypertension and chronic kidney disease. Advanced age and male sex were significantly more frequent in COVID-19[SUP]+[/SUP] than in COVID-19[SUP]-[/SUP] PD patients. The COVID-19 inpatient mortality rate was much higher in PD patients than in non-PD patients (35.4% vs. 20.7%, P < 0.001), especially in patients aged 75-79 years. Of note, overall inpatient mortality of PD patients was significantly higher in 2020 than in 2019 (5.7% vs. 4.9%, P < 0.001).
Conclusions: PD inpatients are more frequently affected by COVID-19 and suffer from increased COVID-19-associated mortality in comparison to non-PD patients. More comprehensive studies are needed to assess the significance of associated comorbidities for COVID-19 risk and mortality in PD. ? 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Keywords: COVID-19 mortality; COVID-19 risk factors; Parkinson's disease; epidemiology; hospitalization.
 
Back
Top Bottom